Skip to main content
MTNB logo

Matinas BioPharma Holdings, Inc.

MTNBNYSEAMERICANHealthcareBiotechnology

$2.37Today:- (-)1Y +39.08%

As of Oct 16, 2026 close

Market cap
$1.03M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$0.48$13.60
Volume (live)
-
Avg. volume (3M)
99.52K

Matinas BioPharma Holdings (MTNB) Income Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Matinas BioPharma Holdings posted a net loss of $10.96M, compared with a net loss of $24.25M a year earlier.

Matinas BioPharma Holdings Income Statement Analysis

Values in millions USD

Scroll to see more
Matinas BioPharma Holdings, Inc. income statement - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Mar 2019Dec 2017
Revenue & Gross Profit
Revenue0.000.001.103.190.030.160.090.120.15
Cost of Revenue0.090.9714.4916.6814.5814.3611.236.799.01
Gross Profit-0.46-0.971.10-13.49-14.55-14.20-11.14-6.67-8.86
Operating Expenses
Research & Development0.0911.4314.4916.6814.5814.3611.236.799.01
Selling, General & Administrative6.887.7610.3711.1010.1910.017.787.987.64
Operating Expenses6.9619.1924.8611.1010.1910.017.7814.7716.65
Operating Income-6.96-20.16-23.77-24.59-24.74-24.21-18.92-14.65-16.50
Other Income/Expense
Interest Income0.000.000.000.000.000.000.000.000.00
Interest Expense0.000.000.000.000.00-0.010.000.000.00
Other Income/Expense-3.39-4.170.823.591.451.761.550.060.66
Income
Income Before Tax-10.35-24.33-22.94-21.00-23.28-22.45-17.37-14.59-15.84
Income Tax Expense0.00-0.080.000.000.000.000.00-0.51-0.36
Net Income-10.96-24.25-22.94-21.00-23.28-22.45-17.37-14.08-15.49
Net Income - Continuous Operations-10.35-24.25-22.94-21.00-23.28-22.45-17.37-14.08-15.49
Net Income - Discontinued Operations---------
EBITDA-6.92-19.19-23.37-20.64-23.00-23.92-18.59-14.43-16.40
EBIT-6.96-20.16-23.77-24.59-24.74-24.21---
Depreciation & Amortization0.460.970.390.360.280.290.330.220.10
Earnings Per Share
Basic EPS-30.00-75.00-79.00-45.00-76.00-6.00-81.00-108.00-128.00
Diluted EPS-2.00-75.00-5.00-45.00-76.00-6.00-81.00-108.00-128.00
Basic Shares Outstanding0.360.320.290.290.283.940.190.130.12
Diluted Shares Outstanding0.360.320.290.290.283.940.190.130.12

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Matinas BioPharma Holdings Financial Statements

Is Matinas BioPharma Holdings profitable?

No. Matinas BioPharma Holdings reported a net loss of $10.96M in fiscal 2025. In fiscal 2024 it lost $24.25M.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition